<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lu X</submitter><funding>Intramural NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Cancer Institute</funding><pagination>7318</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8677766</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>Proteasome substrate receptor hRpn13 is a promising anti-cancer target. By integrated in silico and biophysical screening, we identified a chemical scaffold that binds hRpn13 with non-covalent interactions that mimic the proteasome and a weak electrophile for Michael addition. hRpn13 Pru domain binds proteasomes and ubiquitin whereas its DEUBAD domain binds deubiquitinating enzyme UCHL5. NMR revealed lead compound XL5 to interdigitate into a hydrophobic pocket created by lateral movement of a Pru β-hairpin with an exposed end for Proteolysis Targeting Chimeras (PROTACs). Implementing XL5-PROTACs as chemical probes identified a DEUBAD-lacking hRpn13 species (hRpn13&lt;sup>Pru&lt;/sup>) present naturally with cell type-dependent abundance. XL5-PROTACs preferentially target hRpn13&lt;sup>Pru&lt;/sup>, ca</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.</pubmed_title><pmcid>PMC8677766</pmcid><funding_grant_id>ZIA BC011490</funding_grant_id><funding_grant_id>ZIA BC011627</funding_grant_id><funding_grant_id>1 ZIA BC011490</funding_grant_id><funding_grant_id>1 ZIA BC011627</funding_grant_id><pubmed_authors>Chari R</pubmed_authors><pubmed_authors>Dyba M</pubmed_authors><pubmed_authors>Matsuo H</pubmed_authors><pubmed_authors>Andresson T</pubmed_authors><pubmed_authors>Swenson RE</pubmed_authors><pubmed_authors>Walters KJ</pubmed_authors><pubmed_authors>Osei-Amponsa V</pubmed_authors><pubmed_authors>Chan KC</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Das S</pubmed_authors><pubmed_authors>Choudhari S</pubmed_authors><pubmed_authors>Tran B</pubmed_authors><pubmed_authors>Fromont C</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Evans CN</pubmed_authors><pubmed_authors>Tarasov SG</pubmed_authors><pubmed_authors>Sabbasani VR</pubmed_authors><pubmed_authors>Tarasova NI</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Schwieters CD</pubmed_authors><pubmed_authors>King JC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.</name><description>Proteasome substrate receptor hRpn13 is a promising anti-cancer target. By integrated in silico and biophysical screening, we identified a chemical scaffold that binds hRpn13 with non-covalent interactions that mimic the proteasome and a weak electrophile for Michael addition. hRpn13 Pru domain binds proteasomes and ubiquitin whereas its DEUBAD domain binds deubiquitinating enzyme UCHL5. NMR revealed lead compound XL5 to interdigitate into a hydrophobic pocket created by lateral movement of a Pru β-hairpin with an exposed end for Proteolysis Targeting Chimeras (PROTACs). Implementing XL5-PROTACs as chemical probes identified a DEUBAD-lacking hRpn13 species (hRpn13&lt;sup>Pru&lt;/sup>) present naturally with cell type-dependent abundance. XL5-PROTACs preferentially target hRpn13&lt;sup>Pru&lt;/sup>, ca</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-05-09T01:27:52.315Z</modification><creation>2022-02-11T14:48:19.637Z</creation></dates><accession>S-EPMC8677766</accession><cross_references><pubmed>34916494</pubmed><doi>10.1038/s41467-021-27570-4</doi></cross_references></HashMap>